Published in J Cereb Blood Flow Metab on September 01, 1991
Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A (1996) 1.78
Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage (2007) 1.67
In Vivo Measurement of GABA Transmission in Healthy Subjects and Schizophrenia Patients. Am J Psychiatry (2015) 1.51
Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med (2009) 1.44
Striatal dopaminergic denervation and gait in healthy adults. Exp Brain Res (2007) 1.21
Multi-graphical analysis of dynamic PET. Neuroimage (2009) 1.10
A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies. Neuroimage (2008) 1.05
Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol (2007) 1.04
Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects. Neuropsychopharmacology (2008) 1.03
Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab (2012) 0.93
Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. Neurosci Lett (2007) 0.93
Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects. EJNMMI Res (2012) 0.91
Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry (1993) 0.91
The Effect of Body Posture on Brain Glymphatic Transport. J Neurosci (2015) 0.87
Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology (2012) 0.86
Kinetic modelling of [11C]flumazenil using data-driven methods. Eur J Nucl Med Mol Imaging (2008) 0.86
Compartmental modeling of 11C-HOMADAM binding to the serotonin transporter in the healthy human brain. J Nucl Med (2008) 0.85
[11C]flumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levels. PLoS One (2012) 0.84
Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography. Eur J Nucl Med Mol Imaging (2006) 0.83
Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging (2006) 0.81
Quantitative amyloid imaging using image-derived arterial input function. PLoS One (2015) 0.80
Relative equilibrium plot improves graphical analysis and allows bias correction of standardized uptake value ratio in quantitative 11C-PiB PET studies. J Nucl Med (2012) 0.79
Selection of weighting factors for quantification of PET radioligand binding using simplified reference tissue models with noisy input functions. Phys Med Biol (2012) 0.78
Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. Br J Clin Pharmacol (2005) 0.78
Quantification of human brain benzodiazepine receptors using [18F]fluoroethylflumazenil: a first report in volunteers and epileptic patients. Eur J Nucl Med Mol Imaging (2003) 0.77
Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAChT in nonhuman primates. Nucl Med Biol (2015) 0.77
Quantification of [11C]GB67 binding to cardiac alpha1-adrenoceptors with positron emission tomography: validation in pigs. Eur J Nucl Med Mol Imaging (2008) 0.77
Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain. EJNMMI Res (2017) 0.75
Compartmental modeling of [(11)C]MENET binding to the norepinephrine transporter in the healthy human brain. Nucl Med Biol (2016) 0.75
Altered GABAA receptor density and unaltered blood-brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis. J Cereb Blood Flow Metab (2015) 0.75
Improved Visualization and Specific Binding for Metabotropic Glutamate Receptor Subtype 1 (mGluR1) Using [11C]ITMM with Ultra-High Specific Activity in Small-Animal PET. PLoS One (2015) 0.75
Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study. Biomed Res Int (2016) 0.75
Use of a standardized uptake value for parametric in vivo imaging of benzodiazepine receptor distribution on [11C]flumazenil brain PET. Eur J Nucl Med Mol Imaging (2004) 0.75
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol (1997) 10.06
Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol (1979) 5.83
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med (1995) 4.44
Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science (2001) 3.48
Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol (1980) 3.12
A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol (1984) 3.11
Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal (1997) 3.10
Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med (1994) 2.76
Posterior cingulate cortex in Alzheimer's disease. Lancet (1994) 2.11
Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol (1990) 2.07
History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology (2009) 2.01
Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med (1993) 1.93
Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr (1995) 1.88
In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology (1999) 1.86
Epileptic patterns of local cerebral metabolism and perfusion in humans determined by emission computed tomography of 18FDG and 13NH3. Ann Neurol (1980) 1.78
Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol (1982) 1.77
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
Metabolic mapping of the brain's response to visual stimulation: studies in humans. Science (1981) 1.75
Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol (2000) 1.73
Comparative localization of epileptic foci in partial epilepsy by PCT and EEG. Ann Neurol (1982) 1.73
Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol (2001) 1.67
Mutual information for automated unwarping of rat brain autoradiographs. Neuroimage (1997) 1.60
Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med (1983) 1.55
Three-dimensional stereotactic surface projection analysis of macaque brain PET: development and initial applications. J Nucl Med (2000) 1.54
Correlation methods for the centering, rotation, and alignment of functional brain images. J Nucl Med (1990) 1.52
Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med (1987) 1.51
Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab (1999) 1.49
MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology (1987) 1.49
The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol (1983) 1.47
Pathophysiology, treatment and outcome following severe head injury in children. Childs Brain (1979) 1.46
In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol (1996) 1.45
Pathological findings underlying focal temporal lobe hypometabolism in partial epilepsy. Ann Neurol (1982) 1.43
A simple synthesis of [11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol (1997) 1.43
Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med (1995) 1.42
Quantitation in positron emission computed tomography: 2. Effects of inaccurate attenuation correction. J Comput Assist Tomogr (1979) 1.41
Technetium-99m-N1-(2-mercapto-2-methylpropyl)-N2-(2-propargylthio-2- methylpropyl)-1,2-benzenediamine (T691): preclinical studies of a potential new tracer of regional cerebral perfusion. J Nucl Med (1992) 1.40
N-13 ammonia as an indicator of myocardial blood flow. Circulation (1981) 1.35
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol (1996) 1.35
Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology (2000) 1.33
Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology (1996) 1.32
Interictal cerebral glucose metabolism in partial epilepsy and its relation to EEG changes. Ann Neurol (1982) 1.32
Quantitation in positron emission computed tomography: 5. Physical--anatomical effects. J Comput Assist Tomogr (1981) 1.27
Reorganizing data from transverse section scans of the brain using digital processing. Radiology (1968) 1.26
Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. J Nucl Med (1994) 1.25
Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol (1998) 1.24
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol (2003) 1.23
Computed tomography of intracerebral hematomas. I. Transmission CT observations on hematoma resolution. AJR Am J Roentgenol (1977) 1.23
Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab (1982) 1.21
Patterns of human local cerebral glucose metabolism during epileptic seizures. Science (1982) 1.21
Dual-[11C]tracer single-acquisition positron emission tomography studies. J Cereb Blood Flow Metab (2001) 1.20
Positron emission tomographic analysis of cerebral structures activated specifically by repetitive noxious heat stimuli. J Neurophysiol (1994) 1.20
Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J Nucl Med (1996) 1.18
Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology (2003) 1.18
ECAT: a new computerized tomographic imaging system for positron-emitting radiopharmaceuticals. J Nucl Med (1978) 1.17
Quantifying local cerebral blood flow by N-isopropyl-p-[123I]iodoamphetamine (IMP) tomography. J Nucl Med (1982) 1.17
Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol (1991) 1.17
Positron emission tomographic measurement of cerebral blood flow and permeability-surface area product of water using [15O]water and [11C]butanol. J Cereb Blood Flow Metab (1987) 1.16
Crossed cerebellar diaschisis: occurrence and resolution demonstrated with PET during carotid temporary balloon occlusion. AJNR Am J Neuroradiol (1992) 1.16
Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med (2001) 1.16
Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med (1996) 1.15
Imaging the vesicular monoamine transporter. Adv Neurol (2001) 1.15
Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur J Pharmacol (2000) 1.14
Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab (1997) 1.13
Quantitation in positron emission computed tomography: 4. Effect of accidental coincidences. J Comput Assist Tomogr (1981) 1.13
Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin. J Nucl Med (1979) 1.11
Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab (1999) 1.11
NCA 16 alpha-[18F]fluoroestradiol-17 beta: the effect of reaction vessel on fluorine-18 resolubilization, product yield, and effective specific activity. Int J Rad Appl Instrum A (1986) 1.10
Local cerebral blood volume in head-injured patients. Determination by emission computed tomography of 99mTc-labeled red cells. J Neurosurg (1980) 1.10
Metabolic fate of [13N]ammonia in human and canine blood. J Nucl Med (1990) 1.09
Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology (1999) 1.08
Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med (1984) 1.08
Summary of a National Institute of Mental Health workshop: developing animal models of anxiety disorders. Psychopharmacology (Berl) (2001) 1.08
The brain scan in Sturge-Weber syndrome. Radiology (1972) 1.08
The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease. Ann Neurol (2001) 1.08
Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry (2001) 1.08
PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. J Nucl Med (1995) 1.07